Alzheimer's, Imaging, and Biomarkers (ADNI)

Integrated Neuroscience Session

Tuesday, April 28, 1:00–5:00 p.m.

This session will report the results of the Alzheimer's Disease Neuroimaging Initiative (ADNI) which is a clinical/congnitive, PET, MRI, and CSF biomarker study of elderly controls, MCI, and Alzheimer's disease subjects. In particular, the session will focus on those imaging and CSF biomarkers which measure disease progression with the highest statistical power, and which best identify subjects with AD pathology, especially AD pathology in subjects with no or mild impairments. The results of ADNI are a step in the direction of defining AD pathology with imaging and biomarker measurements.

• IN3-1.001 Gray and White Matter Atrophy in Alzheimer's Disease: A Comparative Study using Subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI), Jim Nikelski, PhD
• IN3-1.002 The ADAS-cog's performance as a measure–lessons from the ADNI study: Part 3–do the scale modifications add value?, Jeremy Hobart, FRCP, PhD
• IN3-1.003 Pre- and Clinical Dementia with Amyloid Deposition using PIB PET Imaging, Shizuo Hatashita, MD, PhD
• IN3-1.004 APOE Status Predicts PiB-Positivity in Nondemented Aging: Evidence for Preclinical Alzheimer's Disease, John C. Morris, MD
• IN3-1.005 Mapping correlations between serum Abeta and tau and hippocampal atrophy measures in 282 ADNI subjects, Liana G. Apostolova, MD
• IN3-1.006 Amyloid beta (Aβ) effects on cognition are mediated by cell injury (Tau) and death (progressive atrophy), Charles DeCarli, MD

• IN3-2.001 ApoE genotype is associated with rate of hippocampal atrophy independent of clinical diagnosis: data from the ADNI study, Evan Fletcher, PhD
• IN3-2.002 In vivo mapping of amyloid toxicity in Alzheimer's disease, Giovanni Frisoni, MD
• IN3-2.003 Regional Rates of Brain Atrophy are Significantly Associated with Rates of Cognitive Decline even after Adjusting for Clinical Syndrome, Dan Mungas, PhD
• IN3-2.004 Quantifying the Correspondence between Tissue Atrophy and Mini-Mental State Exam (MMSE) Scores: Morphometry and Behavior in Alzheimer's Disease Neuroimaging Initiative (ADNI) Subjects, Jim Nikelski, PhD
• IN3-2.005 Mappying the Progression of Atrophy in Early and Late Onset Sporadic Alzheimer's Disease: A Tensor-Based Morphometry Study, Raffaella Migliaccio, MD, PhD
• IN3-2.006 White Matter Hyperintensities, Incident MRI Infarcts Correlate with Cognition (ADNI Study), Jing He, MD
• IN3-2.007 Susceptibility-weighted Imaging in Mild Cognitive Impairment, Antao Du, MD
• IN3-2.008 Regional Differences in White Matter Integrity Distinguish Cognitively Normal Late-Middle-Aged Individuals at Increased Genetic Risk for Alzheimer's Disease, Adam S. Fleisher, MD
• IN3-2.009 Use of a Monoclonal Anti-Aβ Antibody with Biochemical and Imaging Biomarkers to Determine Amyloid Plaque Load in Patients with Alzheimer's Disease (AD) and Control Subjects, Eric R. Siemers, MD
• IN3-2.010 Mapping hippocampal atrophy in mild cognitive impairment and Alzheimer's disease, Liana G. Apostolova, MD

• 3:30–4:00 p.m. Alzheimer's Disease Neuroimaging Initiative (ADNI) Overview, Michael Weiner, MD
• 4:00–4:30 p.m. Quantitative MRI in ADNI, Clifford Jack, MD
• 4:30–5:00 p.m. FDG PET and PiB Imaging in ADNI ,William Jagust, MD